Comparative Pharmacology
Head-to-head clinical analysis: P A S SODIUM versus PASKALIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: P A S SODIUM versus PASKALIUM.
P.A.S. SODIUM vs PASKALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
P.A.S. (p-aminosalicylic acid) sodium is a bacteriostatic agent that competitively inhibits the synthesis of folic acid in Mycobacterium tuberculosis by antagonizing the incorporation of p-aminobenzoic acid (PABA) into dihydrofolate. It is selective for mycobacterial folate synthase.
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
Oral: 4 g three times daily (total daily dose 12 g); IV: 12 g daily in 2-4 divided doses.
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
None Documented
None Documented
1 hour (normal renal function); prolonged to 5-7 hours in anuria or severe renal impairment; clinical context: requires frequent dosing or renal dose adjustment
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min).
Renal (80% as active drug and metabolites, primarily acetylated form); fecal (minor; <10%)
Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%).
Category C
Category C
Antitubercular Agent
Antitubercular Agent